Article
Targeting a neoantigen derived from a common TP53 mutation.
Science (New York, N.Y.) - 5 Mar 2021
Hsiue Emily Han-Chung, Wright Katharine M, Douglass Jacqueline, Hwang Michael S, Mog Brian J, Pearlman Alexander H, Paul Suman, DiNapoli Sarah R, Konig Maximilian F, Wang Qing, Schaefer Annika, Miller Michelle S, Skora Andrew D, Azurmendi P Aitana, Murphy Michael B, Liu Qiang, Watson Evangeline, Li Yana, Pardoll Drew M, Bettegowda Chetan, Papadopoulos Nickolas, Kinzler Kenneth W, Vogelstein Bert, Gabelli Sandra B, Zhou Shibin
Abstract excerpt
TP53 (tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as TP53, are not yet available. Here, we describe the identification of an antibody highly specific to the most common TP53 mutation (R175H, in which arginine at position 175 is replaced with histidine) in complex with a common human leukocyte antigen-A (HLA-A) allele on the cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.